| Period | HQY | SPY | Delta |
|---|---|---|---|
| 3M | +11.8% | +11.4% | +0.4% |
| 6M | -5.6% | +8.2% | -13.7% |
| 1Y | -17.0% | +22.9% | -39.8% |
| Metric | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Total revenue | $191.6M+8.8% | $176.0M+11.9% | $157.3M |
| Total cost of revenue | $28.0M-10.5% | $31.3M+15.4% | $27.1M |
| Gross profit | $913.1M+17.5% | $777.3M+24.8% | $622.6M |
| Sales and marketing | $95.2M+5.0% | $90.7M+14.5% | $79.3M |
| Technology and development | $262.5M+9.6% | $239.5M+9.5% | $218.8M |
| General and administrative | $119.9M-9.3% | $132.3M+27.6% | $103.7M |
| Amortization of acquired intangible assets | $108.0M-3.5% | $111.9M+20.6% | $92.8M |
| Merger integration | $5.0M-87.6% | $40.5M+288.5% | $10.4M |
| Total operating expenses | $590.7M-3.9% | $614.9M+21.8% | $504.9M |
| Income from operations | $322.5M+98.6% | $162.3M+37.9% | $117.7M |
| Interest expense | -$57.1M+5.8% | -$60.6M-9.3% | -$55.5M |
| Other income, net | $12.1M-15.5% | $14.3M+12.0% | $12.8M |
| Total other expense | -$45.0M+2.8% | -$46.3M-8.5% | -$42.7M |
| Income before income taxes | $277.4M+139.1% | $116.0M+54.6% | $75.0M |
| Income tax provision | $62.2M+221.9% | $19.3M+0.0% | $19.3M |
| Net income | $215.2M+122.5% | $96.7M+73.6% | $55.7M |
| Basic (in usd per share) | $2500.00+125.2% | $1110.00+70.8% | $650.00 |
| Diluted (in usd per share) | $2460.00+125.7% | $1090.00+70.3% | $640.00 |
| Basic (in shares) | 86.1M-0.8% | 86.9M+1.5% | 85.6M |
| Diluted (in shares) | 87.5M-1.5% | 88.8M+2.2% | 87.0M |
| Service | |||
| Custodial | |||
| Interchange | |||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
HealthEquity beat Q1 FY2027 expectations with EPS of $0.82 on $354.6M revenue, raised full-year guidance
“HealthEquity delivered strong first‑quarter results, with Adjusted EBITDA margin expanding to 46% and a raised fiscal 2027 outlook”
| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | 2026-06-01 | Wellborn Gayle Furgurson | Director | Sale | 2,439 | $90.00 | $220K | 19.7K | View | |
| 2026-05-28 | 2026-06-01 | Ladd Delano | EVP, General Counsel | Sale | 7,500 | $90.00 | $675K | 91.1K | View | |
| 2025-12-19 | 2025-12-23 | Ladd Delano | EVP, General Counsel | Sale | 1,500 | $94.72 | $142K | 74.0K | View | |
| 2025-11-20 | 2025-11-24 | Ladd Delano | EVP, General Counsel | Sale | 1,500 | $104.56 | $157K | 75.5K | View | |
| 2025-10-20 | 2025-10-22 | Ladd Delano | EVP, General Counsel | Sale | 1,500 | $92.07 | $138K | 77.0K | View |
Informational purposes only, not investment advice.